Passage Bio (PASG) Stock
Biotech developer researching gene therapies for rare brain conditions. Here's the price, business snapshot, and what's worth knowing about Passage Bio in October 2026.
Passage Bio Inc (PASG) is a clinical-stage biotechnology company developing AAV-based gene therapies for rare monogenic central nervous system disorders. Investors should know the business is focused on scientific research and early-stage clinical development rather than current product sales, so revenue and profits are likely limited or non-existent. The company's small market capitalisation suggests limited liquidity and higher share-price volatility compared with larger peers. Key value drivers are clinical trial readouts, regulatory decisions and potential partnerships or licensing deals, all of which carry binary outcomes and long timelines. Development-stage biotechs often face substantial financing needs and dilution risk if they raise capital. For general education: this profile is not investment advice — gene therapy stocks can offer significant upside but also meaningful downside, and Passage Bio suits investors who understand biotech risk, can tolerate potential loss, and are prepared for a long investment horizon.
Passage Bio (PASG) Stock Forecast
Analyst price target, next 12 months
$9.83
+166.5% vs today's $3.69
Price range over the last 12 months
Close to its 12-month low
Analysts covering Passage Bio have a consensus 12-month target of $9.83, above the current price of $3.69.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 29 Jun 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Passage Bio's stock, with a target price indicating potential growth.
Financial Health
Passage Bio Inc has a solid cash flow, but its book value indicates room for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Early-stage catalyst watch
Clinical readouts and regulatory milestones can create sharp share-price moves, though outcomes are binary and performance can vary.
Rare disease focus
Concentrating on rare monogenic neurological disorders can mean high scientific value if successful, but small patient populations and regulatory hurdles add uncertainty.
High scientific risk
Gene therapy development is technically complex and capital-intensive; investors should expect dilution risk and long timelines.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
